11 Organisations from 6 EU Countries
The i-PROGNOSIS consortium includes 11 partners from 6 countries, all members of the European Union, namely, Greece (3), Belgium (1), Germany (2), Portugal (2), Sweden (1) and United Kingdom (1). All partners have excellent experience and capabilities related to the i-PROGNOSIS objectives and tasks in technological, health and healthy ageing policy domains.
GREECE |
|
![]() |
Aristotle University of Thessaloniki Signal Processing and Biomedical Technology Unit Multimedia Understanding Group Dept. of Electrical & Computer Engineering Medical Physics Laboratory Dept. of Neurology Medical School |
![]() |
Center for Research and Technology Hellas Information Technologies Institute |
![]() |
Microsoft Innovation Center Greece |
![]() |
COSMOTE Mobile Telecommunications S.A. |
BELGIUM |
|
![]() |
Age Platform Europe |
GERMANY |
|
![]() |
Technische Universitat Dresden Dept. of Neurology |
![]() |
Fraunhofer Institute for Intelligent Analysis and Information Systems |
PORTUGAL |
|
![]() |
Faculdade de Motricidade Humana Universidade de Lisboa |
![]() |
PLUX – Wireless Biosignals S.A. |
SWEDEN |
|
![]() |
Karolinska Institutet Dept. of Neurobiology, Care Sciences & Society |
UNITED KINGDOM |
|
![]() |
King’s College London, King’s College Hospital Dept. of Basic and Clinical Neuroscience |
OUR STRENGTHS
Medical expertise
Medical partners of i-PROGNOSIS (KCL, TUD, AUTH, KI) are experts in Parkinson’s Disease and have experience in the roll out of health information technology (IT) programmes (KCL, TUD, AUTH, KI).
Technical expertise
Technical and engineering partners (AUTH, CERTH, COSMOTE, PLUX, FHM, FRAUNHOFER, MICROSOFT) have the necessary technical expertise so as to develop the individual modules of the i-PROGNOSIS platform and to integrate them into a robust system that can be deployed for early detection of Parkinson’s, as well as for the human intervention studies.
Policies expertise
i-PROGNOSIS partner AGE has a deep understanding of health/aging policy issues, necessary for highlighting the potential benefits and impacts of i-PROGNOSIS.